Literature DB >> 15993579

Molecular changes in prostatic cancer.

S R J Bott1, M Arya, I S Shergill, M Williamson.   

Abstract

Prostate cancer is one of the most commonly diagnosed and potentially devastating cancers in men, throughout the world. However, the clinical manifestation of this disease varies greatly, from indolent tumours, requiring little or no treatment, to those aggressive cancers which require radical therapies. Prostate cancer, like all other cancers, develops and progresses as a consequence of an accumulation of genetic changes. While several putative genes have been isolated for the development of breast, ovarian and colon cancer, the aetiology and pathogenesis of prostate cancer remains poorly understood. In this review, we discuss important genetic markers in early, metastatic and hormone refractory prostate cancer which may, in the future, be used as markers for diagnosis and prognosis, as well as targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993579     DOI: 10.1016/j.suronc.2005.05.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  4 in total

1.  No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population.

Authors:  Ilke H Onen; Ece Konac; Muzaffer Eroglu; Cagri Guneri; Hasan Biri; Abdullah Ekmekci
Journal:  Mol Biol Rep       Date:  2007-01-11       Impact factor: 2.316

Review 2.  The complexity of prostate cancer: genomic alterations and heterogeneity.

Authors:  Lara K Boyd; Xueying Mao; Yong-Jie Lu
Journal:  Nat Rev Urol       Date:  2012-11       Impact factor: 14.432

3.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01

4.  Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification.

Authors:  Yan Ting Chiang; Peter W Gout; Colin C Collins; Yuzhuo Wang
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.